Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IKBKB_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IKBKB_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IKBKB_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00108031 | Oral cavity | LP | regulation of tumor necrosis factor-mediated signaling pathway | 21/4623 | 47/18723 | 2.17e-03 | 1.58e-02 | 21 |
GO:007135619 | Oral cavity | LP | cellular response to tumor necrosis factor | 76/4623 | 229/18723 | 2.24e-03 | 1.62e-02 | 76 |
GO:000647016 | Oral cavity | LP | protein dephosphorylation | 89/4623 | 281/18723 | 4.60e-03 | 2.93e-02 | 89 |
GO:00022231 | Oral cavity | LP | stimulatory C-type lectin receptor signaling pathway | 10/4623 | 18/18723 | 4.91e-03 | 3.06e-02 | 10 |
GO:19908401 | Oral cavity | LP | response to lectin | 10/4623 | 18/18723 | 4.91e-03 | 3.06e-02 | 10 |
GO:19908581 | Oral cavity | LP | cellular response to lectin | 10/4623 | 18/18723 | 4.91e-03 | 3.06e-02 | 10 |
GO:003530513 | Oral cavity | LP | negative regulation of dephosphorylation | 19/4623 | 45/18723 | 7.33e-03 | 4.09e-02 | 19 |
GO:004366618 | Oral cavity | LP | regulation of phosphoprotein phosphatase activity | 23/4623 | 58/18723 | 8.34e-03 | 4.52e-02 | 23 |
GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
GO:004593625 | Oral cavity | EOLP | negative regulation of phosphate metabolic process | 105/2218 | 441/18723 | 1.05e-12 | 2.46e-10 | 105 |
GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
GO:001056325 | Oral cavity | EOLP | negative regulation of phosphorus metabolic process | 105/2218 | 442/18723 | 1.22e-12 | 2.60e-10 | 105 |
GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
GO:000647023 | Oral cavity | EOLP | protein dephosphorylation | 72/2218 | 281/18723 | 1.19e-10 | 1.35e-08 | 72 |
GO:000283121 | Oral cavity | EOLP | regulation of response to biotic stimulus | 80/2218 | 327/18723 | 1.31e-10 | 1.43e-08 | 80 |
GO:00607592 | Oral cavity | EOLP | regulation of response to cytokine stimulus | 49/2218 | 162/18723 | 2.70e-10 | 2.45e-08 | 49 |
GO:00019592 | Oral cavity | EOLP | regulation of cytokine-mediated signaling pathway | 46/2218 | 150/18723 | 5.71e-10 | 4.44e-08 | 46 |
GO:001988224 | Oral cavity | EOLP | antigen processing and presentation | 36/2218 | 106/18723 | 1.96e-09 | 1.26e-07 | 36 |
GO:003530424 | Oral cavity | EOLP | regulation of protein dephosphorylation | 32/2218 | 90/18723 | 4.22e-09 | 2.41e-07 | 32 |
GO:003530322 | Oral cavity | EOLP | regulation of dephosphorylation | 39/2218 | 128/18723 | 1.39e-08 | 6.43e-07 | 39 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa05170210 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0521216 | Esophagus | ESCC | Pancreatic cancer | 62/4205 | 76/8465 | 7.37e-09 | 6.85e-08 | 3.51e-08 | 62 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0513526 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
hsa05171211 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
hsa0522020 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IKBKB | SNV | Missense_Mutation | | c.1703G>T | p.Arg568Met | p.R568M | O14920 | protein_coding | tolerated(0.17) | benign(0.015) | TCGA-A1-A0SM-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
IKBKB | SNV | Missense_Mutation | | c.1552N>A | p.Glu518Lys | p.E518K | O14920 | protein_coding | deleterious(0.02) | possibly_damaging(0.758) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
IKBKB | SNV | Missense_Mutation | | c.2068N>G | p.Gln690Glu | p.Q690E | O14920 | protein_coding | tolerated(0.46) | benign(0.127) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
IKBKB | SNV | Missense_Mutation | | c.742N>T | p.Asp248Tyr | p.D248Y | O14920 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
IKBKB | insertion | Nonsense_Mutation | novel | c.76_77insGTAAAGAAACACGTGACCTCGGCGATGCTCAGAAGTAGG | p.Phe26delinsCysLysGluThrArgAspLeuGlyAspAlaGlnLysTerVal | p.F26delinsCKETRDLGDAQK*V | O14920 | protein_coding | | | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
IKBKB | SNV | Missense_Mutation | | c.1557N>T | p.Gln519His | p.Q519H | O14920 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
IKBKB | SNV | Missense_Mutation | | c.1008G>C | p.Leu336Phe | p.L336F | O14920 | protein_coding | deleterious(0) | possibly_damaging(0.483) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IKBKB | SNV | Missense_Mutation | | c.782N>G | p.Tyr261Cys | p.Y261C | O14920 | protein_coding | tolerated(0.18) | benign(0.007) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
IKBKB | SNV | Missense_Mutation | novel | c.1820N>G | p.Val607Gly | p.V607G | O14920 | protein_coding | tolerated(0.07) | benign(0.01) | TCGA-AA-3692-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | PD |
IKBKB | SNV | Missense_Mutation | novel | c.1027N>A | p.Asp343Asn | p.D343N | O14920 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-AA-3975-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | MLN-0415 | MLN-0415 | |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | IMD-1041 | IMD-1041 | |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | Arsenic trioxide | | |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3545265 | MLN-0415 | |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | Parthenolide | PARTHENOLIDE | |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | 6-METHOXYCOMAPARVIN 5-METHYL ETHER | CHEMBL256967 | 18088098 |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3545168 | IMD-1041 | |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | 6-METHOXYCOMAPARVIN | CHEMBL401565 | 18088098 |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | BMS-345541 | BMS-345541 | 18702457 |
3551 | IKBKB | SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | ALSTERPAULLONE | ALSTERPAULLONE | |